Maryland Oncology Hematology- Site Number : 8400038

Washington D.C., District of Columbia 20017

1 studies enrolling now · 1 studies all time

What they study most

Plasma Cell Myeloma Refractory

Studies at this site

• A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma — Recruiting now